152 related articles for article (PubMed ID: 16699857)
1. Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice.
Matsuzaki Y; Nagai D; Ichimura E; Goda R; Tomura A; Doi M; Nishikawa K
J Gastroenterol; 2006 Mar; 41(3):231-9. PubMed ID: 16699857
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes.
Kang P; Dalvie D; Smith E; Zhou S; Deese A
Drug Metab Dispos; 2007 Jul; 35(7):1081-8. PubMed ID: 17403914
[TBL] [Abstract][Full Text] [Related]
3. [Sex-difference on flutamide metabolism in rat liver microsomal cytochrome P450 1A2].
Wang HX; Li D; Xu CJ; Liu X
Yao Xue Xue Bao; 2002 Aug; 37(8):608-10. PubMed ID: 12567773
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of flutamide-induced hepatotoxicity in mice by Xian-Ling-Gu-Bao through induction of CYP1A2.
Ding Y; Ma H; Xu Y; Yang F; Li Y; Shi F; Lu Y
J Ethnopharmacol; 2021 Oct; 278():114299. PubMed ID: 34090906
[TBL] [Abstract][Full Text] [Related]
5. Role of enzymatic N-hydroxylation and reduction in flutamide metabolite-induced liver toxicity.
Ohbuchi M; Miyata M; Nagai D; Shimada M; Yoshinari K; Yamazoe Y
Drug Metab Dispos; 2009 Jan; 37(1):97-105. PubMed ID: 18832480
[TBL] [Abstract][Full Text] [Related]
6. Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients.
Goda R; Nagai D; Akiyama Y; Nishikawa K; Ikemoto I; Aizawa Y; Nagata K; Yamazoe Y
Drug Metab Dispos; 2006 May; 34(5):828-35. PubMed ID: 16507648
[TBL] [Abstract][Full Text] [Related]
7. Transport, metabolism, and hepatotoxicity of flutamide, drug-drug interaction with acetaminophen involving phase I and phase II metabolites.
Kostrubsky SE; Strom SC; Ellis E; Nelson SD; Mutlib AE
Chem Res Toxicol; 2007 Oct; 20(10):1503-12. PubMed ID: 17900172
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of flutamide and 2-hydroxyflutamide and their effects on CYP1A2 mRNA in primary rat hepatocytes.
Wang HX; Ma XC; Deng QL; Li D
Acta Pharmacol Sin; 2002 Jun; 23(6):562-6. PubMed ID: 12060533
[TBL] [Abstract][Full Text] [Related]
9. Comparison of in vitro bioactivation of flutamide and its cyano analogue: evidence for reductive activation by human NADPH:cytochrome P450 reductase.
Wen B; Coe KJ; Rademacher P; Fitch WL; Monshouwer M; Nelson SD
Chem Res Toxicol; 2008 Dec; 21(12):2393-406. PubMed ID: 19548358
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2.
Shet MS; McPhaul M; Fisher CW; Stallings NR; Estabrook RW
Drug Metab Dispos; 1997 Nov; 25(11):1298-303. PubMed ID: 9351907
[TBL] [Abstract][Full Text] [Related]
11. Induction of liver cytochrome P450 1A2 expression by flutamide in rats.
Wang HX; Liu X; Xu CJ; Ma XC; Long JE; Li D
Acta Pharmacol Sin; 2005 Nov; 26(11):1382-6. PubMed ID: 16225762
[TBL] [Abstract][Full Text] [Related]
12. Flutamide metabolism in four different species in vitro and identification of flutamide metabolites in human patient urine by high performance liquid chromatography/tandem mass spectrometry.
Tevell A; Lennernäs H; Jönsson M; Norlin M; Lennernäs B; Bondesson U; Hedeland M
Drug Metab Dispos; 2006 Jun; 34(6):984-92. PubMed ID: 16540588
[TBL] [Abstract][Full Text] [Related]
13. Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity.
Kashimshetty R; Desai VG; Kale VM; Lee T; Moland CL; Branham WS; New LS; Chan EC; Younis H; Boelsterli UA
Toxicol Appl Pharmacol; 2009 Jul; 238(2):150-9. PubMed ID: 19442681
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes.
Fau D; Eugene D; Berson A; Letteron P; Fromenty B; Fisch C; Pessayre D
J Pharmacol Exp Ther; 1994 Jun; 269(3):954-62. PubMed ID: 8014883
[TBL] [Abstract][Full Text] [Related]
15. Bioactivation of flutamide metabolites by human liver microsomes.
Kang P; Dalvie D; Smith E; Zhou S; Deese A; Nieman JA
Drug Metab Dispos; 2008 Jul; 36(7):1425-37. PubMed ID: 18411402
[TBL] [Abstract][Full Text] [Related]
16. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice.
Zaher H; Buters JT; Ward JM; Bruno MK; Lucas AM; Stern ST; Cohen SD; Gonzalez FJ
Toxicol Appl Pharmacol; 1998 Sep; 152(1):193-9. PubMed ID: 9772215
[TBL] [Abstract][Full Text] [Related]
17. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients.
Gomez JL; Dupont A; Cusan L; Tremblay M; Suburu R; Lemay M; Labrie F
Am J Med; 1992 May; 92(5):465-70. PubMed ID: 1349790
[TBL] [Abstract][Full Text] [Related]
18. Increased basal expression of hepatic Cyp1a1 and Cyp1a2 genes in inbred mice selected for susceptibility to acetaminophen-induced hepatotoxicity.
Casley WL; Menzies JA; Mousseau N; Girard M; Moon TW; Whitehouse LW
Pharmacogenetics; 1997 Aug; 7(4):283-93. PubMed ID: 9295056
[TBL] [Abstract][Full Text] [Related]
19. Role of CYP1A2 in the hepatotoxicity of acetaminophen: investigations using Cyp1a2 null mice.
Tonge RP; Kelly EJ; Bruschi SA; Kalhorn T; Eaton DL; Nebert DW; Nelson SD
Toxicol Appl Pharmacol; 1998 Nov; 153(1):102-8. PubMed ID: 9875304
[TBL] [Abstract][Full Text] [Related]
20. Saccharomyces cerevisiae intervention for relieving flutamide-induced hepatotoxicity in male rats.
Mannaa F; Ahmed HH; Estefan SF; Sharaf HA; Eskander EF
Pharmazie; 2005 Sep; 60(9):689-95. PubMed ID: 16222870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
